Oxford, UK – 11 March 2019: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading gene and cell therapy group, notes Axovant’s update on the Phase 2 SUNRISE-PD…
London, UK – 8 February 2019: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, will be announcing its Preliminary Results for the…
Oxford, UK – 7 February 2019: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading gene and cell therapy group, has been informed that as part of a…
Oxford, UK – 06 December 2018: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, notes an announcement today by Axovant Sciences regarding…
Oxford, UK – 01 December 2018: Oxford Biomedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis on the…
Oxford, UK – 23 November 2018: Oxford Biomedica plc (“OXB” or “the Group”), a leading gene and cell therapy group, today announces the formation of a new digital framework initiative…
Oxford, UK – 25 October 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, notes that its partner, Axovant Sciences (NASDAQ:AXON), a…
London, UK – 5 October 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces additional details of its strategic alliance…
Lentiviral vector bioprocessing market expected to grow to $800m by 2026 Oxford BioMedica adds fourth facility in Oxford allowing the Group to target 25% to 30% of global lentiviral vector…
Oxford, UK – 13 September 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announces interim results for the six…
London, UK – 28 August 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today notes that the European Commission (EC) has…
Oxford, UK – 6 August 2018: Oxford BioMedica plc (LSE:OXB) (“Oxford BioMedica” or “the Group”), a leading gene and cell therapy group, today announces that it has entered into a…